dm+d

109109007

Articles

Safety in Lactation: Metabolic disorders

18 September 2020These drugs are used for a variety of metabolic conditions, most of which are rare, and therefore give very limited opportunity to assess their impact…
Search Articles

Refrigerated Storage

Cystadrops, 3.8 mg/mLOrphan Europe UK Limited

Orphan Europe UK Limited
Cystadrops, 3.8 mg/mL
Eye drops solution

In-house stability data from the manufacturer for this product supports, that continuous or episodic exposure to temperatures from:
-20°C to 2°C for a period of time up to 7 days,
8°C to 15°C for a period of time up to 7 days,
15°C to 25°C for a period of time up to 3 days does not affect the quality of the product nor will the exposure reduce these products total shelf life.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

No - as described above
Yes
5 August 2020
London MI Service

Medicine Compliance Aid Stability

CystagonOrphan Europe UK Ltd

Orphan Europe UK Ltd
Cystagon
Capsules 50mg, 150mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Packaging includes a dessicant.
29 March 2015

Lactation Safety Information

Cysteamine for nephropathic cystinosis

Cysteamine for nephropathic cystinosis
No
No published evidence of safety
High dose animal studies have shown serious adverse effects in breastfed young animals. The relevance of this to human breast milk is unknown
24 September 2020